Quantitative characterization of CTLA4 trafficking and turnover using a combined in vitro and in silico approach

Sahamoddin Khailaie, Behzad Rowshanravan, Philippe A. Robert, Lucy S. K. Walker, David M. Sansom, Michael Meyer‐HermannbioRxiv 2017 · DOI

TL;DR

This paper develops a quantitative model of CTLA4 trafficking within cells, combining experimental data with mathematical simulations. This approach allows researchers to precisely measure CTLA4's movement, degradation, and recycling rates, providing a crucial framework for understanding immune regulation and developing targeted therapies.

What Problem Does This Paper Address?

CTLA4 is a critical protein that acts as a "brake" on the immune system, preventing over-activation that could lead to autoimmunity or attacks on healthy tissues. While its importance is well-established, the precise mechanisms governing its cellular journey – how it's made, where it goes, and how quickly it's broken down – have remained somewhat elusive. This lack of quantitative understanding limits our ability to predict how CTLA4's function might be altered in disease or by therapeutic interventions. The authors aim to fill this gap by providing a detailed, quantitative model of CTLA4 trafficking.

Methods

The core of this work is a systems biology approach that integrates experimental data with mathematical modeling. The researchers developed a series of ordinary differential equations (ODEs) to describe the dynamic processes of CTLA4 synthesis, internalization, recycling, and degradation. They then used experimental data from cell lines (CHO cells) and primary human T cells to "fit" these models, estimating the kinetic rates of these various trafficking steps. This involved designing specific experiments to block or measure individual processes, and then using computational methods to simultaneously optimize model parameters against all available data. The paper also details how they adapted their models for specific experimental protocols, such as antibody staining assays, to extract meaningful parameters.

Datasets

The study utilized experimental data generated from:

  • CHO cells: These cell lines were engineered to express human CTLA4 and were used in various assays to measure internalization, synthesis, and degradation.
  • Primary human T cells: Data from these cells were also incorporated to ensure the model's relevance to native immune responses.

The paper does not introduce new benchmark datasets but rather uses existing experimental data, re-analyzed and integrated within their modeling framework.

Key Insights and Ideas

  • CTLA4's "storage" in the cytoplasm: A significant portion of CTLA4 resides in the cytoplasm, acting as a reservoir that can quickly replenish surface levels. This cytoplasmic pool is crucial for maintaining CTLA4's function.
  • Fast internalization, slower recycling: CTLA4 is rapidly internalized from the cell surface, but its recycling back to the surface is considerably slower. This imbalance contributes to its overall cellular dynamics.
  • Lysosomal degradation is key: The majority of CTLA4 degradation occurs via the lysosomal pathway, and blocking this pathway dramatically slows down CTLA4 turnover.
  • Ligand binding affinity matters, but not always linearly: The efficiency of CTLA4 interacting with its ligands (like CD80/CD86) is influenced by binding affinity, but the relationship isn't straightforward. There's an optimal range for off-rates, and very high or very low affinities can lead to inefficient ligand removal.
  • Therapeutic implications: The model can predict how changes in ligand affinity or the use of anti-CTLA4 antibodies might affect CTLA4 function, offering a tool for drug development and personalized medicine.

Key Results

  • The study successfully quantified key CTLA4 trafficking rates, including internalization (kᵢ ≈ 0.291 min⁻¹), recycling (kᵣ ≈ 0.021 min⁻¹), and degradation (δ ≈ 0.0044 min⁻¹ for lysosomal, δ<0xE2><0x82><0x99> ≈ 0.0002 min⁻¹ for non-lysosomal).
  • They demonstrated that CTLA4 is primarily degraded through the lysosomal pathway, with inhibition of this pathway leading to a ~96% reduction in degradation rate and a ~2.7-hour to 59-hour increase in half-life.
  • The model accurately predicted that blocking CTLA4 synthesis leads to a rapid decrease in surface CTLA4, which is only partially compensated by cytoplasmic stores.
  • The study showed that recycling is essential for maintaining surface CTLA4 expression, with a blocked recycling process leading to rapid clearance.
  • Simulations revealed that ligand uptake is fastest for ligands with higher on-rates (higher affinity) and exhibits a maximum efficiency at intermediate off-rates.

Limitations and Future Work

  • Model Simplifications: The models, while comprehensive, make certain assumptions, such as the availability of antibodies in staining experiments (thermic bath approximation) and rapid antibody binding.
  • Focus on Kinetics: The current model primarily focuses on the kinetics of CTLA4 and its interaction with ligands/antibodies. It doesn't fully capture the complex downstream signaling events or the spatial organization within the immunological synapse in extreme detail.
  • Transferability: The authors suggest that the methodology for extracting trafficking rates can be transferred to other transmembrane proteins, which is a significant future direction.
  • Therapeutic Predictions: The framework is poised for further exploration of how mutations in CTLA4 or its ligands, or the design of novel therapeutic antibodies, might impact immune responses.
  • LRBA Deficiency: The paper touches upon LRBA deficiency, suggesting future work to further refine models of CTLA4 regulation in the context of genetic disorders.

Summary updated

Abstract

Abstract CTLA4 is an essential negative regulator of T cell immune responses and is a key checkpoint regulating autoimmunity and anti-tumour immunity. Genetic mutations resulting in a quantitative defect in CTLA4 are associated with the development of an immune dysregulation syndrome. Endocytosis of CTLA4 is rapid and continuous with subsequent degradation or recycling. CTLA4 has two natural ligands, the surface transmembrane proteins CD80 and CD86 that are shared with the T cell co-stimulatory receptor CD28. Upon ligation with CD80/CD86, CTLA4 can remove these ligands from the opposing cells by transendocytosis. The efficiency of ligand removal is thought to be highly dependent on the processes involved in CTLA4 trafficking. With a combined in vitro-in silico study, we quantify the rates of CTLA4 internalization, recycling and degradation. We incorporate experimental data from cell lines and primary human T cells. Our model provides a framework for exploring the impact of altered affinity of natural ligands or therapeutic anti-CTLA4 antibodies and for predicting the effect of clinically relevant CTLA4 pathway mutations. The presented methodology for extracting trafficking rates can be transferred to the study of other transmembrane proteins.
BibTeX
@misc{khailaie2017quantitative,
  author = {Sahamoddin Khailaie and Behzad Rowshanravan and Philippe A. Robert and Lucy S. K. Walker and David M. Sansom and Michael Meyer‐Hermann},
  title = {{Quantitative characterization of CTLA4 trafficking and turnover using a combined <i>in vitro</i> and <i>in silico</i> approach}},
  year = {2017},
  doi = {10.1101/106898},
  howpublished = {bioRxiv},
}

Loading related content...

Figure